Microvolt T-wave alternans testing provides a reliable means of guiding anti-arrhythmic therapy
Author(s)
Hohnloser, Stefan H.; Cohen, Richard J.
Download20120407-Letter to American Heart Journal.pdf (15.55Kb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Terms of use
Metadata
Show full item recordAbstract
Gupta et al1 present a meta-analysis and conclude that microvolt T-wave alternans testing (MTWA) does not modify risk of sudden cardiac death (SCD) sufficiently for clinical use. Their analysis involves a number of methodological limitations. The authors included in their primary analysis numerous surrogates for sudden cardiac death (SCD) such as ICD therapy, cardiac mortality and total mortality.
Date issued
2012-10Department
Whitaker College of Health Sciences and Technology; Harvard University--MIT Division of Health Sciences and TechnologyJournal
American Heart Journal
Publisher
Elsevier B.V.
Citation
Hohnloser, Stefan H., and Richard J. Cohen. Microvolt T-wave Alternans Testing Provides a Reliable Means of Guiding Anti-arrhythmic Therapy. American Heart Journal 164, no. 4 (October 2012): e7.
Version: Author's final manuscript
ISSN
00028703